KIF20A and breast cancer: Masako Nakamura’s research elucidates KIF20A’s pronounced expression in different breast cancer subtypes compared to normal tissue, identifying it as an independent marker of prognosis and a potential target for therapy, with its suppression resulting in a halted cell cycle and cancer cell death [29].